Trials / Terminated
TerminatedNCT01965730
Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery
The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epsilon-aminocaproic acid (EACA) |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2013-10-18
- Last updated
- 2019-05-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01965730. Inclusion in this directory is not an endorsement.